Robert L. Ferris

University of North Carolina at Chapel Hill — United States

Medicine · Health Sciences

113h-index55.4kcitations1.2kworks2.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Head and Neck Cancer Studies(411), Cancer Immunotherapy and Biomarkers(373), Immunotherapy and Immune Responses(188), Lung Cancer Treatments and Mutations(133), CAR-T cell therapy research(130)

Publications1.2k total

Postoperative Lymph Is a Proximal Source of ctDNA for Detection of Recurrence in HPV-Independent Head and Neck Cancer.
UNC Libraries·2026Open Access
A Multi-Year Collaborative Curriculum Improves Multidisciplinary Team Members’ Ability to Comprehensively Care for Patients With Squamous Cell Carcinoma of the Head and Neck
Ear Nose & Throat Journal·2025Open Access
INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Clinical Cancer Research·2025Open Access
Serum Arginase−1 is a predictive biomarker for melanoma patients and a surrogate indicator of systemic myeloid cell fitness
UNC Libraries·2025Open Access
Trends in the Use of Neoadjuvant Systemic Therapy for Head and Neck Squamous Cell Carcinoma
UNC Libraries·2025Open Access
Serum Arginase−1 is a predictive biomarker for melanoma patients and a surrogate indicator of systemic myeloid cell fitness
OncoImmunology·2025Open Access
Reply to: Noncomparative Comparisons: The Paradox of Randomized Noncomparative Trials
Journal of Clinical Oncology·2025
Supplemental Table 3 from Response to Neoadjuvant Targeted Therapy in Operable Head and Neck Cancer Confers Survival Benefit
2025Open Access
Supplemental Figure 1 from Response to Neoadjuvant Targeted Therapy in Operable Head and Neck Cancer Confers Survival Benefit
2025Open Access
Supplemental Table 2 from Response to Neoadjuvant Targeted Therapy in Operable Head and Neck Cancer Confers Survival Benefit
2025Open Access
Figure S1 from Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Figures 1-3 from Cetuximab Responses in Patients with HNSCC Correlate to Clonal Expansion Feature of Peripheral and Tumor-Infiltrating T Cells with Top T-Cell Receptor Clonotypes
2025Open Access
Supplemental Figure 2 from Response to Neoadjuvant Targeted Therapy in Operable Head and Neck Cancer Confers Survival Benefit
2025Open Access
Supplemental Table 4 from Response to Neoadjuvant Targeted Therapy in Operable Head and Neck Cancer Confers Survival Benefit
2025Open Access
Supplementary File 1 from Cetuximab Responses in Patients with HNSCC Correlate to Clonal Expansion Feature of Peripheral and Tumor-Infiltrating T Cells with Top T-Cell Receptor Clonotypes
2025Open Access
Supplementary Data1 from Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
2025Open Access
Supplementary Tables 1-2 from Cetuximab Responses in Patients with HNSCC Correlate to Clonal Expansion Feature of Peripheral and Tumor-Infiltrating T Cells with Top T-Cell Receptor Clonotypes
2025Open Access
Supplemental Table 1 from Response to Neoadjuvant Targeted Therapy in Operable Head and Neck Cancer Confers Survival Benefit
2025Open Access
Figure S2 from Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
2025Open Access
Integrating artificial intelligence-driven digital pathology and genomics to establish patient-derived organoids as new approach methodologies for drug response in head and neck cancer
Oral Oncology·2025· 1 citedOpen Access
page 1 of 62Next →

Frequent Co-authors

Raja R. Seethala(8), Umamaheswar Duvvuri(8), William E. Gooding(8), Sally E. Carty(7), Yuri E. Nikiforov(6), Marina N. Nikiforova(6), Seungwon Kim(6), Simion I. Chiosea(6), Lisa Licitra(5), Kevin J. Harrington(5), Robert I. Haddad(5), Makoto Tahara(5), Maura L. Gillison(5), Linwah Yip(5), Tullia C. Bruno(5), Jérôme Fayette(4), A. Dimitrios Colevas(4), Caroline Even(4), Ian Ganly(4), Barbara Burtness(4)